Alzheimer’s disease is a progressive and devastating brain disorder that affects nearly seven million Americans. Recently, the Food and Drug Administration (FDA) approved a promising new therapy—Donanemab, marketed as Kisunla by Eli Lilly—for individuals in the early stages of the disease.

Alzheimer’s disease is characterized by the accumulation of amyloid plaques in the brain, which are linked to cognitive decline and memory loss. This new treatment, Kisunla, is administered via a monthly 30-minute infusion that aims to slow the disease progression by an average of four to seven months in eligible patients.

The cost of Kisunla treatment can reach up to $32,000 per year, depending on the duration needed. Individual response to the medication varies; brain scans show some patients require treatment for as little as six months, while others may need 12 to 18 months. Many patients do not pay the full price due to insurance coverage, including Medicare Part B, which covers a portion of the cost after meeting deductibles.

Like any medical treatment, Kisunla carries some risks, such as brain swelling and bleeding. It’s important to discuss these potential side effects with your healthcare provider to make an informed decision.

While it doesn’t offer a cure, Kisunla can improve quality of life by slowing disease progression. For individuals and families affected by Alzheimer’s disease, this drug offers new hope.